<DOC>
	<DOCNO>NCT00551512</DOCNO>
	<brief_summary>The purpose research study find answer follow question : 1 . What high dose CBP501 cisplatin safely administer consecutive 2-hours 1-hour infusion every 21 day ? 2 . What side effect combination CBP501 cisplatin give infusion every 21 day ? 3 . What amount CBP501 cisplatin find blood certain time give ? 4 . Are substances blood tumor tell u tumor sensitivity CBP501 cisplatin ? 5 . Will CBP501 give cisplatin help treat cancer ?</brief_summary>
	<brief_title>Phase I Study CBP501 Cisplatin Patients With Advanced Refractory Solid Tumors</brief_title>
	<detailed_description>9.1 23BOverall Study Design Plan This open-label , multicenter , dose-escalation pharmacokinetic Phase I study CBP501 cisplatin administer consecutive IV infusion accord once-every-3-weeks schedule patient advance solid tumor refractory standard therapy . The study conduct three US center . During course study , amendment introduce ( # 3 , October 17th , 2007 ; see section X9.8X ) allow administration unique dose single agent CBP501 prior initiation combination therapy enable completion pharmacokinetic ( PK ) characterization single agent CBP501 . Pharmacodynamic analysis involve phosphoserine 216 evaluation also remove . See section X16.1.1X copy protocol protocol amendment . With 8 additional patient include recommend dose ( DL6 ) , decide stop PK CTC sampling ( therefore day-7 CBP501 alone infusion ) , sufficient information retrieve . In addition , base evidence efficacy observe ovarian cancer patient , 10 ovarian 4 endometrial cancer patient include recommended dose ; patient assess DLT confirm identification MTD . Case Report Forms use collect data , data management carry AAIOncology . All laboratory data Investigator observation transcribe CRF . ECG , U/S , MRI CT scan report summary CRF . The original report , trace film retain Investigators future reference . See section X16.1.2X sample CRF .</detailed_description>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Signed informed consent obtain prior initiation studyspecific procedure . Pathologicallyconfirmed , locally advanced metastatic solid tumor , refractory standard therapy . Male female patient age 18 year . ECOG Performance Status ( PS ) : 01 . Life expectancy &gt; 3 month . Previous anticancer treatment must discontinue least 3 week prior first dose study treatment ( 6 week mitomycin C ; 6 week antiandrogen therapy discontinue prior treatment initiation , exception 8 week bicalutamide ) . Adequate organ function include follow : Bone Marrow : absolute neutrophil count ( ANC ) ³ 1.5 x 109/L , platelet count ³ 100 x 109/L , hemoglobin ³ 9 g/dL Hepatic : Bilirubin £ 1.5 x upper limit normal ( ULN ) , aspartate transaminase ( AST/SGOT ) alanine transaminase ( ALT/SGPT ) £ 2.5 x ULN ( ≤ 5 x ULN liver metastasis present ) , INR £ 1.5 x ULN Renal : Serum creatinine ≤ 1.5 mg/dL creatinine clearance ³ 70 mL/min ( calculate accord Cockroft Gault formula ) Metabolic : serum potassium , calcium magnesium ³ low limit normal ( LLN ) Creatine phosphokinase isoenzymes : CPKMB , CPKMM ≤ ULN Troponin I serum level within normal value Female patient childbearing potential must negative pregnancy test use least one form contraception approve investigator 4 week prior study 4 month last dose study drug . For purpose study , childbearing potential define : `` All female patient unless postmenopausal least one year surgically sterile '' . Male patient must use form barrier contraception approve investigator study 4 month last dose study drug . Ability cooperate treatment followup . Radiation therapy 30 % bone marrow prior entry study . Prior chemotherapy nitrosoureas high dose carboplatin ( AUC &gt; 6 mg/mL ) , prior mitomycin C cumulative dose ³ 25 mg/m² , prior bone marrow transplant intensive chemotherapy stem cell support . Presence serious concomitant systemic disorder incompatible study ( e.g . uncontrolled congestive heart failure , active infection , etc. ) . Any previous history another malignancy ( cure basal cell carcinoma skin cure insitu carcinoma cervix ) within 5 year study entry . Presence significant central nervous system psychiatric disorder ( ) would hamper patient 's compliance . Evidence peripheral neuropathy &gt; grade 1 accord NCICTCAE Version 3 . Treatment investigational agent , participation another clinical trial within 28 day prior study entry . Pregnant breastfeeding patient patient childbearing potential use adequate contraception . Known HIV , HBV , HCV infection . Active CNS metastasis : patient history CNS metastases eligible treat stable without symptom 4 week completion treatment , image documentation require , must either steroid stable dose steroid &gt; 1 week prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>cancer</keyword>
	<keyword>solid tumor</keyword>
</DOC>